Patents by Inventor Ralph B. Arlinghaus
Ralph B. Arlinghaus has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20170088623Abstract: This document provides prophylactic methods for reducing cancer metastasis by targeting LCN2, MMP9, and CX-CR4.Type: ApplicationFiled: September 30, 2015Publication date: March 30, 2017Applicants: Ingeneron, Inc., Board of Regents, The University of Texas SystemInventors: Eckhard U. Alt, Ralph B. Arlinghaus, Michael E. Coleman
-
Patent number: 8338366Abstract: A nanoparticle-polypeptide complex comprising a bioactive polypeptide in association with a nanoparticle, wherein the bioactive polypeptide is modified by the addition of a chemical moiety that facilitates cellular uptake of the protein. The polypeptide can be a protein or a peptide. In some embodiments, the amino acid sequence of the protein or peptide is derived from the amino acid sequence of a tumor suppressor gene product.Type: GrantFiled: March 14, 2006Date of Patent: December 25, 2012Assignee: The Board of Regents of the University of the Texas SystemInventors: Jacki Lin, Ralph B. Arlinghaus, Tong Sun, Lin Ji, Bulent Ozpolat, Gabriel Lopez-Berestein, Jack A. Roth
-
Publication number: 20120219561Abstract: This document provides prophylactic methods for reducing cancer metastasis by targeting LCN2, MMP9, and CX-CR4.Type: ApplicationFiled: August 2, 2010Publication date: August 30, 2012Applicants: Ingeneron, Inc., Board of Regents, The University of Texas SystemInventors: Eckhard U. Alt, Ralph B. Arlinghaus, Michael E. Coleman
-
Patent number: 7923548Abstract: The present invention provides novel compositions and methods for use in the treatment of cancer, specifically, in the treatment of chronic myelogenous leukemia (CML). The compositions contain antisense oligonucleotides that hybridize to Grb2 and Crkl nucleic acids, the gene products of which are known to interact with the tumorigenic protein bcr-abl. Used alone, in conjunction with each other, and even in conjunction with antisense oligonucleotides directed to bcr-abl nucleic acids, these compositions inhibit the proliferation of CML cancer cells.Type: GrantFiled: April 3, 2007Date of Patent: April 12, 2011Assignee: Board of Regents, The University of Texas SystemInventors: Gabriel Lopez-Berestein, Ana M. Tari, Ralph B. Arlinghaus
-
Publication number: 20080274104Abstract: The present invention concerns targeting a cell death factor associated with cancer. More specifically, an apoptosis-inducing factor is targeted to prevent destruction of non-cancerous cells. The factor may be a lipocalin molecule, and in specific embodiments its secretion and/or the secreted form is targeted by an inhibitory agent, such as an antibody, small molecule, antisense RNA, or siRNA, for example.Type: ApplicationFiled: February 10, 2006Publication date: November 6, 2008Inventors: Ralph B. Arlinghaus, Xie Shanhai, Hui Lin, Sun Tong
-
Patent number: 7319000Abstract: Disclosed are compositions and methods for the prevention and treatment of viral infections. The identification of distinct classes of peptides for use in both anti-viral vaccines and therapeutic formulations is reported. Peptide formulations are disclosed which enhance the systemic distribution, activity, and longevity of anti-viral cytotoxic T cells, and/or which protect human cells from HIV infection.Type: GrantFiled: June 5, 1997Date of Patent: January 15, 2008Assignee: Board of Regents, the University of Texas SystemInventors: Jagannadha K. Sastry, Ralph B. Arlinghaus, Chris D. Platsoucas, Pramod N. Nehete
-
Patent number: 7309692Abstract: The present invention provides novel compositions and methods for use in the treatment of cancer, specifically, in the treatment of chronic myelogenous leukemia (CML). The compositions contain antisense oligonucleotides that hybridize to Grb2 and Crk1 nucleic acids, the gene products of which are known to interact with the tumorigenic protein bcr-abl. Used alone, in conjunction with each other, and even in conjunction with antisense oligonucleotides directed to bcr-abl nucleic acids, these compositions inhibit the proliferation of CML cancer cells.Type: GrantFiled: July 8, 1996Date of Patent: December 18, 2007Assignee: Board of Regents, The University of Texas SystemInventors: Gabriel Lopez-Berestein, Ana M Tari, Ralph B. Arlinghaus
-
Patent number: 7306804Abstract: This invention discloses diagnostic, preventative, and treatment therapies of AIDS involving determining whether a subject exhibits an HLA-Cw7-restricted CTL response. Some methods are directed to the use of HLA-Cw7 as a genetic marker for long-term non-progression and amenability to treatment therapies. Diagnostic methods include a method for predicting long term non-progression in an HIV-infected subject. Preventative and treatment methods encompass determining whether a subject exhibits or can exhibit an HLA-Cw7-restricted CTL response. They also encompass ways of eliciting such a response, if necessary. Furthermore, some of the methods involve administering one or more HIV polypeptides or peptides, or polynucleotides encoding them, as a treatment therapy to prevent the development of AIDS.Type: GrantFiled: September 29, 2003Date of Patent: December 11, 2007Assignee: Board of Regents, the University of Texas SystemInventors: K. Jagannadha Sastry, Ralph B. Arlinghaus, Pramod N. Nehete
-
Patent number: 7220853Abstract: The present invention provides novel compositions and methods for use in the treatment of cancer, specifically, in the treatment of chronic myelogenous leukemia (CML). The compositions contain antisense oligonucleotides that hybridize to Grb2 and Crkl nucleic acids, the gene products of which are known to interact with the tumorigenic protein bcr-abl. Used alone, in conjunction with each other, and even in conjunction with antisense oligonucleotides directed to bcr-abl nucleic acids, these compositions inhibit the proliferation of CML cancer cells.Type: GrantFiled: December 20, 2002Date of Patent: May 22, 2007Assignee: Board of Regents, The University of Texas SystemInventors: Gabriel Lopez-Berestein, Ana M. Tari, Ralph B. Arlinghaus
-
Bcr-Abl directed compositions and uses for inhibiting Philadelphia chromosome stimulated cell growth
Publication number: 20040022772Abstract: Compositions comprising or encoding one or more peptides that inhibit the Bcr—Abl oncoprotein and that bind to molecules involved in Bcr—Abl function are disclosed. The peptides and polypeptides inhibit the growth of, and induce cell death of, Philadelphia chromosome-positive leukemia cells expressing the Bcr—Abl oncoprotein. Methods for treating leukemias (e.g., CML, ALL and AML), including autologous bone marrow transplant therapy, using the peptide and polypeptide compositions of the invention are also provided.Type: ApplicationFiled: March 25, 2003Publication date: February 5, 2004Inventors: Ralph B. Arlinghaus, Jiaxin Liu, Gabriel Lopez-Berestein, Dai Lu, Yun Wu -
Patent number: 6656471Abstract: This invention discloses diagnostic, preventative, and treatment therapies of AIDS involving determining whether a subject exhibits an HLA-Cw7-restricted CTL response. Some methods are directed to the use of HLA-Cw7 as a genetic marker for long-term non-progression and amenability to treatment therapies. Diagnostic methods include a method for predicting long term non-progression in an HIV-infected subject. Preventative and treatment methods encompass determining whether a subject exhibits or can exhibit an HLA-Cw7-restricted CTL response. They also encompass ways of eliciting such a response, if necessary. Furthermore, some of the methods involve administering one or more HIV polypeptides or peptides, or polynucleotides encoding them, as a treatment therapy to prevent the development of AIDS.Type: GrantFiled: November 16, 1999Date of Patent: December 2, 2003Assignee: Board of Regents, The University of Texas SystemInventors: K. Jagannadha Sastry, Ralph B. Arlinghaus, Pramod N. Nehete
-
Publication number: 20030153526Abstract: The present invention provides novel compositions and methods for use in the treatment of cancer, specifically, in the treatment of chronic myelogenous leukemia (CML). The compositions contain antisense oligonucleotides that hybridize to Grb2 and Crkl nucleic acids, the gene products of which are known to interact with the tumorigenic protein bcr-abl. Used alone, in conjunction with each other, and even in conjunction with antisense oligonucleotides directed to bcr-abl nucleic acids, these compositions inhibit the proliferation of CML cancer cells.Type: ApplicationFiled: December 20, 2002Publication date: August 14, 2003Inventors: Gabriel Lopez-Berestein, Ana M. Tari, Ralph B. Arlinghaus
-
BCR-ABL directed compositions and uses for inhibiting Philadelphia chromesome stimulated cell growth
Patent number: 6537804Abstract: The present invention provides methods for detecting and quantitating BCR-ABL gene products and other abnormal ABL gene products of Ph1-positive leukemic cells. The invention further provides methods for determining the relative number of leukemic cells compared with normal ABL cells to assess the tumor burden of a patient. In another aspect, the methods of the present invention can be used to determine a specific phase of leukemia, particularly chronic-phase CML.Type: GrantFiled: June 21, 1999Date of Patent: March 25, 2003Assignee: Board of Regents, The University of Texas SystemsInventors: Ralph B. Arlinghaus, Jiaxin Liu, Gabriel Lopez-Berestein, Dai Lu, Yun Wu -
Publication number: 20020151678Abstract: An active peptide consisting essentially of 7 to about 30 residence and having a sequence that corresponds to a conserved domain of an HIV protein is disclosed, as is a multimer containing that peptide, an aqueous composition containing the multimer and methods of using and making the same. The aqueous composition containing an immunologically effective amount of an active peptide multimer, when introduced into an immunocompetent host animal in an immunologically effective amount, is capable of inducing cellular immunity against the native HIV protein to which the active peptide of the multimer corresponds in sequence, but is not capable of inducing production of antibodies that immunoreact with that native HIV protein.Type: ApplicationFiled: July 24, 2001Publication date: October 17, 2002Applicant: Board of Regents, The University of Texas System.Inventor: Ralph B. Arlinghaus
-
Patent number: 6265539Abstract: An active peptide consisting essentially of 7 to about 30 residue and having a sequence that corresponds to a conserved domain of an HIV protein is disclosed, as is a multimer containing that peptide, an aqueous composition containing the multimer and methods of using and making the same. The aqueous composition containing an immunologically effective amount of an active peptide multimer, when introduced into an immunocompetent host animal in an immunologically effective amount, is capable of inducing cellular immunity against the native HIV protein to which the active peptide of the multimer corresponds in sequence, but is not capable of inducing production of antibodies that immunoreact with that native HIV protein.Type: GrantFiled: February 13, 1992Date of Patent: July 24, 2001Assignee: The University of Texas System The Board of RegentsInventor: Ralph B. Arlinghaus
-
Patent number: 6210873Abstract: The present invention discloses a novel method for the rapid screening of candidate cytotoxic T lymphocyte- (CTL-) inducing compounds, such as peptides, by the in vivo priming of CTLs with synthetic peptides. The use of compounds so identified for the development of CTL vaccines for the treatment of various infectious disorders, including the treatment of viral diseases such as AIDS, herpes, influenza, and feline or bovine leukemia, is also disclosed, as is the use of this methodology for the preparation of specifically primed CTLs.Type: GrantFiled: December 2, 1991Date of Patent: April 3, 2001Assignee: Board of Regents, The University of Texas SystemInventors: Jagannadha K. Sastry, Ralph B. Arlinghaus, Chris D. Platsoucas
-
Bcr-Abl directed compositions and uses for inhibiting Philadelphia chromosome stimulated cell growth
Patent number: 6107457Abstract: Compositions comprising a mixture of peptides that bind to molecules involved in Bcr-Abl oncoprotein function are disclosed. In addition, expression of functional BCR protein (p160 BCR) or amino terminal fragments thereof (159, 221 and 413 amino terminal residues) by way of retrovirus vectors will oppose the biological function of Bcr-Abl (p160 BCR) or inactivate Bcr-Abl tyrosine kinase function or its signal transduction function. Bcr and Abl peptides, either tyrosine phosphorylated or unphosphorylated, that bind to a region near the amino terminus of Bcr to prevent formation of tetramer Bcr-Abl molecules, that bind to the SH2 domain of Grb2, to sites on tyrosine phosphorylated Shc protein, to sites of Crkl, and to an SH2 domain of Ras Gap comprise particular peptide preparations of the invention.Type: GrantFiled: February 16, 1995Date of Patent: August 22, 2000Assignee: Board of Regents, The University of Texas SystemInventors: Ralph B. Arlinghaus, Jiaxin Liu, Dai Lu, Gabriel Lopez-Berestein -
Patent number: 5603933Abstract: Disclosed are compositions and methods for use in viral binding and inactivation and in protecting cells from viral infection, particularly, for use in protecting target human CD4.sup.+ cells from infection by HIV. Peptides including short sequences from CD4 are identified as being particularly effective at binding to gp120 and inhibiting or reducing HIV infection of human CD4.sup.+ cells by steric hinderance or catalytic inactivation of gp120. The invention thus encompasses improved CD4-based peptide compositions and therapeutic formulations with viral binding and HIV-inhibitory activity.Type: GrantFiled: August 31, 1993Date of Patent: February 18, 1997Assignee: Board of Regents, The University of TexasInventors: Victor A. Dwyer, IV, Jagannada K. Sastry, Ralph B. Arlinghaus, Pramod N. Nehete
-
Patent number: 5369008Abstract: The present invention provides methods for detecting and quantitating BCR-ABL gene products and other abnormal ABL gene products of Ph.sup.1 -positive leukemic cells. The invention further provides methods for determining the relative number of leukemic cells compared with normal ABL cells to assess the tumor burden of a patient. In another aspect, the methods of the present invention can be used to determine a specific phase of leukemia, particularly chronic-phase CML.Type: GrantFiled: November 12, 1993Date of Patent: November 29, 1994Assignee: Board of Regents, The University of Texas SystemInventors: Ralph B. Arlinghaus, Jean Y. J. Wang, Jie O. Guo
-
Patent number: 5128319Abstract: An active peptide consisting essentially of 7 to about 30 residence and having a sequence that corresponds to a conserved domain of an HIV protein is disclosed, as is a multimer containing that peptide, an aqueous composition containing the multimer and methods of using and making the same. The aqueous composition containing an immunologically effective amount of an active peptide multimer, when introduced into an immunocompetent host animal in an immunologically effective amount, is capable of inducing cellular immunity against the native HIV protein to which the active peptide of the multimer corresponds in sequence, but is not capable of inducing production of antibodies that immunoreact with that native HIV protein.Type: GrantFiled: September 20, 1989Date of Patent: July 7, 1992Assignee: Board of Regents, The University of Texas SystemInventor: Ralph B. Arlinghaus